BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

Cephalalgia

Volumn 34, Issue 2, 2014, Pages 114-125

  Marcus, Ronald ^a   Goadsby, Peter J ^b   Dodick, David ^c   Stock, David ^a   Manos, George ^a   Fischer, Tanya Z ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

BMS 927711; Calcitonin gene related peptide; double blind; migraine

Indexed keywords

PLACEBO; RIMEGEPANT; SUMATRIPTAN;

ADULT; ANALGESIA; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HUMAN; JAW PAIN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MUSCLE TIGHTNESS; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHONOPHOBIA; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THORAX PAIN; VOMITING;

BMS-927711; CALCITONIN GENE-RELATED PEPTIDE; DOUBLE-BLIND; MIGRAINE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CALCITONIN GENE-RELATED PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PIPERIDINES; PLACEBOS; PYRIDINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892162373     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413500727     Document Type: Article

References (23)

1. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675
2. Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors for headache recurrence after sumatriptan: A study in 366 migraine patients. Cephalalgia. 1996; 16: 264-269
3. Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004; 44: 414-425
4. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6: 573-582
5. Williamson DJ, Hargreaves RJ, Hill RG, et al. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia. 1997; 17: 518-524
6. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990; 28: 183-187
7. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61
8. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56
9. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312
10. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123
11. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110
12. Akerman S, Williamson DJ, Kaube H, et al. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002; 137: 62-68
13. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004; 142: 1171-1181
14. Summ O, Charbit AR, Andreou AP, et al. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain. 2010; 133: 2540-2548
15. Luo G, Chen L, Conway CM, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3- difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyri din-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem. 2012; 55: 10644-10651
16. Hall DB, Meier U, Diener HC. A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials. Contemp Clin Trials. 2005; 26: 349-364
17. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722
18. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147
19. Longmore J, Shaw D, Smith D, et al. Differential distribution of 5HT1D and 5HT1B-immunoreactivity within the human trigemino-cerebrovacular system: Implications for the discovery of new antimigraine drugs. Cephalalgia. 1997; 17: 833-842
20. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia. 2011; 31: 573-584
21. Stump E. Telacagepant reported to be effective and tolerable for acute migraine. Neurology Today. 2009; 9: 1,8-1,8
22. Chaitman BR, Ho AP, Behm MO, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012; 91: 459-466
23. Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012; 52: 224-235